Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation

@article{AvgilTsadok2015SexDI,
  title={Sex Differences in Dabigatran Use, Safety, And Effectiveness In a Population-Based Cohort of Patients With Atrial Fibrillation},
  author={Meytal Avgil Tsadok and Cynthia A. Jackevicius and Elham Rahme and Karin H. Humphries and Louise Pilote},
  journal={Circulation: Cardiovascular Quality and Outcomes},
  year={2015},
  volume={8},
  pages={593–599}
}
Background—Sex differences were observed with regard to warfarin treatment in patients with atrial fibrillation, with women having a higher risk of stroke compared with men. We aimed to compare sex differences in use, safety, and effectiveness of dabigatran. Methods and Results—We conducted a population-based cohort study of patients with atrial fibrillation using administrative data in Quebec, Canada, 1999 to 2013. Men and women who filled a prescription for dabigatran (110 and 150 mg bid… 
View on Wolters Kluwer
ahajournals.org
48 Citations
Highly Influential Citations
2
Background Citations
6
Results Citations
3

48 Citations

Citation Type

Citation Type

Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation.
Sex differences in treatment strategy and adverse outcomes among patients 75 and older with atrial fibrillation in the MarketScan database
TLDR
Sex differences exist in the treatment of AF among patients aged 75 years and older and women are less likely to receive an anticoagulant and rhythm control treatment, and efforts are needed to enhance use AF therapies among women.
Sex Differences in Oral Anticoagulation and Outcomes of Stroke and Intracranial Bleeding in Newly Diagnosed Atrial Fibrillation
TLDR
In the care of newly diagnosed AF in the United States, women, compared with men, are less likely to receive oral anticoagulation, and this appears to mediate the increased risk of both stroke and hospitalization but also appears to Mediate lower observed intracranial bleeding risk.
Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights
Gender differences in clinical presentation and 1-year outcomes in atrial fibrillation
TLDR
In a ‘real-world’ European AF registry, women were more symptomatic but less likely to receive invasive rhythm control therapy such as electrical cardioversion or ablation and further study is needed to confirm that these differences do not disadvantage women with AF.
Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study.
TLDR
In this population of adults with a diagnosis of atrial fibrillation and a first prescription for an OAC, it was found that patients taking warfarin tended to be poorer, sicker, and less likely to have a cardiologist prescriber, and there was no difference in important clinical outcomes between warFarin and DOACs.
Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation.
TLDR
The absolute treatment benefits and harms of dabig atran in atrial fibrillation can be estimated based on readily available patient characteristics and can be used for shared decision making before starting dabigatran treatment and to determine the optimal dose.
Gender-related Differences in Management of Nonvalvular Atrial Fibrillation in an Asian Population
TLDR
Female patients withAF were treated more conservatively and rhythm control strategies were used less frequently than in males, even though the female patients with AF had more severe symptoms.
Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR ®) PINNACLE Registry
TLDR
Among patients with atrial fibrillation, women were significantly less likely to receive OAC at all levels of the CHA 2 DS 2‐VASc score and despite increasing non–vitamin K OAC use, women had persistently lower rates of Oac use compared to men over time.
Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation.
TLDR
Among older patients admitted with recently diagnosed AF, the risk of stroke was greater in women than in men, regardless of warfarin use, even after adjusting for baseline comorbid conditions, individual components of the CHADS(2) score, and warfar in treatment.
Dabigatran versus warfarin in patients with atrial fibrillation.
TLDR
In patients with atrial fibrillation, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar to those associated with warfarin, as well as lower rates of major hemorrhage.
Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study
TLDR
Increased risk of thromboembolism and bleeding with dabigatran among previous VKA users was unexpected and may reflect patient selection and ‘drug switching’ practices.
Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment.
TLDR
The data show a higher risk of stroke in anticoagulated AF females with respect to males, despite a similar quality of antICOagulation, according to Modified Rankin scale.
Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study.
Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study
TLDR
Women with atrial fibrillation have a moderately increased risk of stroke compared with men, and thus, female sex should be considered when making decisions about anticoagulation treatment, but women younger than 65 years and without other risk factors have a low risk for stroke, and do not need antICOagulant treatment.
Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study
TLDR
Women are at higher risk than men for AF-related thromboembolism off warfarin, and Warfarin therapy appears be as effective in women, if not more so, than in men, with similar rates of major hemorrhage.
Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation
TLDR
In general practice settings, dabigatran was associated with reduced risk of ischemic stroke, intracranial hemorrhage, and death and increased risk of major gastrointestinal hemorrhage compared with warfarin in elderly patients with nonvalvular atrial fibrillation.
Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.
TLDR
Women in these studies were older and had more stroke risk factors; the higher rate of thrombo-embolism among women was related to more frequent interruption of anticoagulant therapy.
Apixaban versus warfarin in patients with atrial fibrillation.
TLDR
In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
...
1
2
3
4
5
...